McKesson (MCK) Stock Forecast & Price Target

$579.74 +0.52 (+0.09%)

(As of 12/20/2024 05:31 PM ET)

McKesson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
2

Buy
14

Based on 16 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 2 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for MCK.

Consensus Price Target

$650.14
12.14% Upside

According to the 16 analysts' twelve-month price targets for McKesson, the average price target is $650.14. The highest price target for MCK is $713.00, while the lowest price target for MCK is $579.00. The average price target represents a forecasted upside of 12.14% from the current price of $579.74.

Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

MCK Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$650.14	$631.57	$620.93	$480.31
Forecasted Upside	12.14% Upside	0.55% Upside	22.23% Upside	5.75% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

McKesson Stock vs. The Competition

Type	McKesson	Medical Companies	S&P 500
Consensus Rating Score	2.94	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	12.14% Upside	25,828.56% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent MCK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/17/2024	Morgan Stanley 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$612.00 ➝ $642.00	+14.35%
12/13/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$535.00 ➝ $641.00	+10.71%
12/4/2024	Mizuho 2 of 5 stars	S. Valiquette Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$630.00	+1.95%
11/13/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$630.00 ➝ $713.00	+13.73%
11/7/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
11/7/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$560.00 ➝ $680.00	+23.79%
Get the Latest News and Ratings for MCK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.
11/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$531.00 ➝ $688.00	+25.25%
10/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$665.00 ➝ $630.00	+29.78%
9/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$623.00 ➝ $579.00	+20.99%
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$656.00 ➝ $661.00	+19.54%
8/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$596.00 ➝ $616.00	+12.78%
6/25/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$590.00 ➝ $670.00	+10.23%
6/24/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$570.00 ➝ $670.00	+11.10%
5/8/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$563.00 ➝ $652.00	+19.74%
5/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$620.00 ➝ $630.00	+14.00%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/11/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$450.00 ➝ $485.00	+11.71%
5/9/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:19 AM ET.

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, December 17, 2024. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

Here are some ways that investors could benefit from investing in McKesson Co.:

McKesson Co. has shown strong institutional support, with 85.07% of its stock owned by institutional investors, indicating confidence in the company's future performance.
The stock is currently trading at $576.40, which is near its 12-month high of $637.51, suggesting a robust market position and potential for further growth.
Recent insider trading activity shows that executives are actively managing their positions, with a notable sale by EVP Leann B. Smith, which can indicate a strategic approach to stock management.
McKesson Co. has a solid market capitalization of $73.17 billion, reflecting its significant size and stability in the healthcare sector.
The company has a relatively low beta of 0.49, suggesting that its stock is less volatile compared to the market, which can be appealing for risk-averse investors.

McKesson
Bear Case

Investors should be bearish about investing in McKesson Co. for these reasons:

Despite the strong institutional ownership, the recent sale of shares by Barclays PLC, which reduced its stake by 18.5%, may raise concerns about the stock's short-term outlook.
The stock has experienced fluctuations, with a 12-month low of $431.35, indicating potential volatility that could deter some investors.
Insider ownership is relatively low at 0.11%, which may suggest a lack of alignment between management and shareholder interests.
The price-to-earnings (P/E) ratio of 29.73 is higher than the industry average, which could indicate that the stock is overvalued compared to its earnings potential.
Recent trading volumes have varied, with only 1,093,719 shares traded on a day when the average volume was 818,423, suggesting potential liquidity concerns.

MCK Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $650.14, with a high forecast of $713.00 and a low forecast of $579.00.
: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCK shares.
: According to analysts, McKesson's stock has a predicted upside of 12.14% based on their 12-month stock forecasts.
: Over the previous 90 days, McKesson's stock had 2 upgrades and 1 downgrade by analysts.
: McKesson has been rated by research analysts at Baird R W, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore ISI, Leerink Partners, Mizuho, Morgan Stanley, Robert W. Baird, and Wells Fargo & Company in the past 90 days.
: Analysts like McKesson more than other "medical" companies. The consensus rating score for McKesson is 2.94 while the average consensus rating score for "medical" companies is 2.81. Learn more on how MCK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

This page (NYSE:MCK) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

McKesson (MCK) Stock Forecast & Price Target